

BBSRC UK VETERINARY VACCINOLOGY RESEARCH NETWORK

Bryan Charleston

Networking and research coordination will be one of the major components of the BBSRC's veterinary vaccinology programme.

BBSRC aims to fund a UK veterinary vaccinology network for a period of five years.

BBSRC UK VETERINARY VACCINOLOGY RESEARCH NETWORK

Q4 2013

Coordination group formed to help manage, prioritize and review network activities

Call for expression of interest and collection of feedback

First meeting, 7th January 2014

Establish priority areas of activity for the network. Define gaps, identify opportunities

Q1 2014

Submit an application to BBSRC to fund a UK veterinary vaccinology network for a period of five years.

BBSRC UK VETERINARY VACCINOLOGY RESEARCH NETWORK

Coordination group

Bryan Charleston - The Pirbright Institute

Gary Entrican - Moredun Research Institute

Glyn Hewinson - Animal Health Veterinary Laboratory Agency

Adrian Hill - The Jenner Institute

Peter Jeffries - GALVmed

Duncan Maskell - University of Cambridge

Ivan Morrison - The Roslin Institute, University of Edinburgh

Randolph Richards - University of Stirling

Fiona Tomley - Royal Veterinary College

BBSRC UK VETERINARY VACCINOLOGY RESEARCH NETWORK

Initial funding to support the network £300,000 over 5 years.

General network meeting Annual

Focused workshops/ meetings 4-5 per year

Applications to support meetings, brief description and costings reviewed by coordination group

Web based communication

Form multi-disciplinary teams to co-ordinate current research activities and develop funding applications, for example, centre for doctoral training (CDT), strategic LoLa applications, EU.

BBSRC UK VETERINARY VACCINOLOGY RESEARCH NETWORK

Consider early engagement with industry to ensure commercial feasibility




Figure 2. Accelerating the vaccine product development pathway. Ways in which candidate vaccines could be advanced to licensure within 8–10 years, if all players in the process are aligned from the outset. IND, investigational new drug application; CTM, clinical trial manufacturing. (Contribution of James Merson, Pfizer.)

BBSRC UK VETERINARY VACCINOLOGY RESEARCH NETWORK

EXPECTED OUTCOMES

Development of a strategic research agenda

Uptake of new tools/technologies in the field of veterinary vaccinology

Progress in the field of understanding protective immunity and developing determinants and biomarkers

Advancement of generic vaccinology approaches

Identification of potential novel vaccine candidates and vaccine approaches

Stimulation of a step change in vaccine development

Improved access to specialized tools and facilities

Increased integration of the human-veterinary vaccinology field (one Health approach)

Improved communication between non-profit sector and industry.